Syncrosome keeps increasing its skills in the Cardiovascular area

Syncrosome keeps increasing its skills in the Cardiovascular area

17 Avr Syncrosome keeps increasing its skills in the Cardiovascular area

In the framework of our development, we are proud to announce our political will to strengthen our capabilities for cardiovascular studies by the recruitment of our new scientific colleague, Guillaume Bourdier.

He will be in charge, with the scientific and technical team, of managing cardiovascular studies and setting up new in vivo Efficacy disease models or approaches and techniques, in reproducible conditions to improve translation of preclinical results.

Guillaume acquired a Master in cardiovascular physiology and a PhD in cardiac physiopathology in 2017. These formations allowed him both develop robust knowledge in cardiac diseases, especially in ischemic diseases and heart failure, echocardiography, etc… and obtain in vivo skills in preclinical study.

He shares our vision and values concerning scientific and process requirements connected with a high quality in customer satisfaction.

Guillaume and all the Syncrosome team will be happy to respond to all your requests, questions or comments!

You can contact us via our mail: dvpt@syncrosome.com

 

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

  • Drug Efficacy Studies in several therapeutic areas :
    • Central Nervous Sytem,
    • Cardiovascular and Metabolic disease,
    • Respiratory,
    • Gastrointestinal
  • Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

No Comments

Post A Comment